key: cord-1021499-37jb9rn9 authors: Beaudoin-Bussières, Guillaume; Chen, Yaozong; Ullah, Irfan; Prévost, Jérémie; Tolbert, William D.; Symmes, Kelly; Ding, Shilei; Benlarbi, Mehdi; Gong, Shang Yu; Tauzin, Alexandra; Gasser, Romain; Chatterjee, Debashree; Vézina, Dani; Goyette, Guillaume; Richard, Jonathan; Zhou, Fei; Stamatatos, Leonidas; McGuire, Andrew T.; Charest, Hughes; Roger, Michel; Pozharski, Edwin; Kumar, Priti; Mothes, Walther; Uchil, Pradeep D.; Pazgier, Marzena; Finzi, Andrés title: A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection date: 2022-01-25 journal: Cell Rep DOI: 10.1016/j.celrep.2022.110368 sha: e515add5517b441e42b45887229ef35ad1ba1ac9 doc_id: 1021499 cord_uid: 37jb9rn9 Emerging evidence indicate that both neutralizing and Fc-mediated effector functions of antibodies contribute to protection against SARS-CoV-2. It is unclear if Fc-effector functions alone can protect against SARS-CoV-2. Here, we isolated CV3-13, a non-neutralizing antibody, from a convalescent individual with potent Fc-mediated effector functions. The cryo-EM structure of CV3-13 in complex with the SARS-CoV-2 Spike reveals that the antibody binds from a distinct angle of approach to an N-terminal domain (NTD) epitope that only partially overlaps with the NTD supersite recognized by neutralizing antibodies. CV3-13 does not alter the replication dynamics of SARS-CoV-2 in K18-hACE2 mice, but its Fc-enhanced version significantly delays virus spread, neuroinvasion and death in prophylactic settings. Interestingly, the combination of Fc-enhanced non-neutralizing CV3-13 with Fc-compromised neutralizing CV3-25 completely protects mice from lethal SARS-CoV-2 infection. Altogether, our data demonstrate that efficient Fc-mediated effector functions can potently contribute to the in vivo efficacy of anti-SARS-CoV-2 antibodies. Neutralizing NTD-directed antibodies target similar glycan-free epitopes located in the 231 upper protruding area of the NTD, referred to as the "NTD supersite" of vulnerability 232 (Cerutti et contribution to the Fab-NTD interface. These substantial structural rearrangement of the 300 NTD are a direct consequence of antibody binding, either by a conformational sampling 301 or an induced-fit mechanism. Collectively, the high immunogenicity and high mutational 302 frequency observed in the flexible NTD loops are likely associated with their increased 303 accessibility to both neutralizing and non-nAbs. 304 305 CV3-13 does not protect K18-hACE2 mice from a SARS-CoV-2 lethal challenge 306 We next investigated the in vivo efficacy of the non-nAb CV3-13 under a prophylactic ( 307 24 h prior) or therapeutic (1and 2 days post infection; dpi) setting to protect or treat K18-308 hACE2 mice from a lethal intranasal SARS-CoV-2 nLuc infection as previously 309 described ( Figure 5A and S5A) (Ullah et al., 2021a) . Longitudinal non-invasive 310 bioluminescence imaging (BLI), body weight change, survival, viral load estimation in 311 brain, lung and nasal cavity and terminal imaging after necropsy showed no difference 312 between isotype-and CV3-13-treated mice under either prophylactic or therapeutic 313 settings ( Figure 5 and S5, panels B-J). Furthermore, mRNA levels of inflammatory 314 cytokines (IL6, CCL2, CXCL10 and IFNG) in brain and lungs were also similar to 315 isotype-treated cohorts ( Figure 5 and S5, panels K, L). These data suggest that natural Fc-316 effector functions associated with CV3-13 were not enough to alter virus replication and 317 dissemination in vivo in the stringent K18-hACE2 mouse model of SARS-CoV-2 318 infection. Thus, in addition to clearing infected cells by engaging innate immune cells 319 through Fc-mediated effector functions, efficient Fab-mediated neutralization of free 320 viruses by antibodies is essential for optimal in vivo efficacy. expected to increase the binding to mouse FcγRs. We first confirmed that the 331 GASDALIE mutations significantly enhanced Fc-mediated effector functions of CV3-13 332 without altering its non-nAb phenotype (Figure 2A , B, E, S4B, C). Next, we carried out 333 temporal BLI to compare SARS-CoV-2-nLuc dissemination in K18-hACE2 mice that 334 were pre-treated with CV3-13 WT and CV3-13 GASDALIE ( Figure 6A ). Whole body 335 quantification of nLuc signal intensities both non-invasively and after necropsy at 4 dpi 336 revealed significant reduction in SARS-CoV-2 replication and neuroinvasion in CV3-13 337 GASDALIE-pre-treated mice compared to isotype and CV3-13 WT pre-treated cohorts 338 ( Figure 6B -E). In addition, immunostaining of brain cryosections with antibodies to 339 SARS-CoV-2 nucleocapsid revealed a marked reduction in infected cells when mice 340 were pre-treated with CV3-13 GASDALIE ( Figure S6A , B). Both CV3-13 WT and CV3-341 13 GASDALIE mAbs decorated the surface of infected neurons suggesting that 342 J o u r n a l P r e -p r o o f introduction of GASDALIE mutations did not hamper antibody penetration into tissue 343 despite enhanced FcR interactions ( Figure S6B ). We also observed a significant 344 difference in body weight loss phenotype and an overall decrease in systemic spread of 345 virus to most tissue analyzed except lungs after necropsy as measured by nLuc flux 346 intensities and viral load analyses by real-time PCR for N mRNA copy numbers ( Figure 347 6F-H, S6C). While viral loads and cytokine mRNA in the lungs were similar between the 348 cohorts, there was a significant decrease in the overall inflammatory cytokine mRNA 349 levels in the brain consistent with reduced viral loads in CV3-13 GASDALIE-treated 350 mice ( Figure 6I ). Thus, our data indicate that prophylaxis with CV3-13 GASDALIE 351 significantly decreases SARS-CoV-2 dissemination and neuroinvasion in mice. 352 353 CV3-13 GASDALIE prophylaxis delays mortality and protects mice from lethal 354 To test if CV3-13 GASDALIE-imposed reduction in virus dissemination had any impact 356 on SARS-CoV-2-induced mortality in K18-hACE2 mice, we extended our experimental 357 end-point to assess survival ( Figure 7A ). In addition to hIgG1-pretreated cohort, we also 358 included mice treated with an unrelated antibody that recognizes the HIV-1 co-receptor 359 binding site on gp120 (17b) carrying GASDALIE mutations as controls. In corroboration 360 with early termination (4 dpi) experiment, our BLI analyses revealed a significant delay 361 in systemic virus spread as well as neuroinvasion in CV3-13 GASDALIE-administered 362 mice compared to control and CV3-13 WT-pre-treated cohorts ( Figure 7B-D) . 363 Accordingly, we also observed a significant deceleration in body-weight loss and 364 mortality for CV3-13 GASDALIE-pre-treated mice ( Figure 7E , F). In addition, viral 365 J o u r n a l P r e -p r o o f loads in nose, brain and lungs were significantly reduced in CV3-13 GASDALIE-366 pretreated group compared to CV3-13-pretreated and control cohorts ( Figure 7G , H). In 367 contrast to 4 dpi, where viral loads in the lungs were comparable to control cohorts, we 368 did observe a significant reduction of viral loads in the lungs of CV3-13 GASDALIE-369 pretreated mice after they had succumbed to infection ( Figure 7H ). These data indicated 370 that CV3-13 GASDALIE required additional time to reduce virus infection in the lungs. 371 However, inflammatory cytokine mRNA expression profile in the lungs remained 372 comparable in CV3-13 GASDALIE-treated mice with significant reduction seen only for 373 Ccl2 and Ifng mRNA levels in the brain tissues as compared to control cohorts. These 374 data demonstrate the potential of non-nAb with enhanced Fc-effector functions to 375 interfere with SARS-CoV-2 spread. 376 We next explored if in vivo efficacy can be improved when Fc-enhanced CV3-13 377 is combined with a nAb. We chose a nAb CV3-25 that binds S2 for the analyses with Fc-378 compromising LALA mutations. Combining nAb CV3-25 LALA with non-nAb CV3-13 379 GASDALIE also allowed us to separate neutralizing and Fc effector functions of 380 antibodies for gaining mechanistic insights into antibody action. Introduction of the 381 GASDALIE and the LALA mutations in CV3-13 and CV3-25, respectively, did not 382 modify their capacity to bind to the Spike or change their neutralizing profile compared 383 to their WT counterparts ( Figure S4A , C). As predicted, these Fc changes affected their 384 capacity to mediate ADCC (i.e. GASDALIE mutations enhanced and LALA mutations 385 decreased ADCC) ( Figure S4B ). As expected due to the different epitopes they 386 recognize, NTD for CV3-13 and S2 for CV3-25, a 1:1 cocktail of CV3-13 GASDALIE 387 and CV3-25 LALA bound the Spike at higher levels than when the individual antibodies 388 Figure S2A ). This is in line with the interpretation 443 that NTD mutations from the emerging variants may be a result of NTD-directed 444 antibody selection, which is compatible with the hypothesis that non-nAb NTD 445 antibodies like CV3-13 influence virus evolution through Fc-mediated effector functions. 446 CV3-13 did not neutralize pseudoviral particles or authentic SARS-CoV-2 viruses 447 but did mediate Fc-effector functions against Spike-expressing cells. We suggest that 448 differences in fine epitope specificity and the angle of approach used by CV3-13 as 449 compared to neutralizing NTD-specific mAbs limit its ability to sterically hinder Spike-450 co-receptor/auxiliary receptor interactions, the prefusion-to-postfusion transition of Spike 451 and/or membrane fusion as has been suggested as a neutralization mechanism for other 452 NTD binding antibodies. However, the mode of CV3-13 binding may enable recognition 453 Images were acquired and analyzed with the manufacturer's Living Image v4.7.3 844 in vivo software package. Image acquisition exposures were set to auto, with imaging 845 parameter preferences set in order of exposure time, binning, and f/stop, respectively. 846 Images were acquired with luminescent f/stop of 2, photographic f/stop of 8. Binning was 847 set to medium. Comparative images were compiled and batch-processed using the image 848 browser with collective luminescent scales. Photon flux was measured as luminescent 849 radiance (p/sec/cm 2 /sr). During luminescent threshold selection for image display, 850 luminescent signals were regarded as background when minimum threshold levels 851 resulted in displayed radiance above non-tissue-containing or known uninfected regions. 852 To determine the pattern of virus spread, the image sequences were acquired every day 853 following administration of SARS-CoV-2 (i.n). Image sequences were assembled and 854 converted to videos using Image J. 855 856 Indicated organs (nasal cavity, brain, lungs from infected or uninfected mice were 858 collected, weighed, and homogenized in 1 mL of serum free RPMI media containing 859 penicillin-streptomycin and homogenized in 2 mL tube containing 1.5 mm Zirconium 860 beads with BeadBug 6 homogenizer (Benchmark Scientific, TEquipment Inc). Virus 861 titers were measured using two highly correlative methods. First, the total RNA was 862 Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as 1213 an early predictor of COVID-19 mortality Syncytia formation by 1216 SARS-CoV-2-infected cells Recent developments in the CCP-EM 1218 software suite Potent Neutralizing Antibodies against SARS-CoV-2 Identified 1221 by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells Potent SARS-CoV-2 neutralizing antibodies directed 1225 against spike N-terminal domain target a single supersite MolProbity: all-atom 1229 structure validation for macromolecular crystallography Human monoclonal antibodies block the binding of SARS-CoV-2 spike 1233 protein to angiotensin converting enzyme 2 receptor A neutralizing human antibody binds to the N-terminal domain of 1236 the Spike protein of SARS-CoV-2 Affinity of human IgG subclasses to 1239 mouse Fc gamma receptors Differential Fc-Receptor Engagement Drives an 1241 Anti-tumor Vaccinal Effect The SARS-CoV-1243 Structure, Function, and Antigenicity: Implications 1244 for the Design of Spike-Based Vaccine Immunogens SAbPred: a structure-based antibody prediction 1247 server High-level and high-throughput 1249 recombinant protein production by transient transfection of suspension-growing human 1250 293-EBNA1 cells Efficacy of ChAdOx1 nCoV-19 1253 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an 1254 exploratory analysis of a randomised controlled trial Coot: model-building tools for molecular graphics Features and development 1258 of Coot Major role of IgM in the neutralizing 1261 activity of convalescent plasma against SARS-CoV-2 Visualizing density maps with 1263 UCSF Chimera UCSF ChimeraX: Meeting modern challenges in visualization and 1266 analysis SARS-CoV-2 1269 variants, spike mutations and immune escape SARS-CoV-2 Cell 1272 Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease 1273 Inhibitor Structure-based design of 1276 prefusion-stabilized SARS-CoV-2 spikes Structural basis for potent 1279 neutralization of SARS-CoV-2 and role of antibody affinity maturation A Study of Ad26.COV2.S for the Prevention of 1282 SARS-CoV-2-Mediated COVID-19 in Adult Participants Isolation and 1285 characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects Human neutralizing antibodies elicited by SARS-CoV-2 infection Inference of macromolecular assemblies from 1291 crystalline state Structure of the SARS-CoV-2 spike receptor-binding domain bound to 1294 the ACE2 receptor Engineered antibody Fc variants with enhanced 1297 effector function CoV-2 infection and influence the neutralizing activity of different classes of antibodies CoV-2 infection-enhancing and neutralizing antibodies Structural Basis and Mode of Action for Two 1307 Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern Macromolecular structure 1311 determination using X-rays, neutrons and electrons: recent developments in Phenix Potent neutralizing antibodies against multiple epitopes on 1315 SARS-CoV-2 spike An infectivity-enhancing site on the 1318 SARS-CoV-2 spike protein targeted by antibodies Clinical and immunological assessment of asymptomatic 1321 SARS-CoV-2 infections Real-Time Conformational Dynamics of SARS-CoV-2 1324 Spikes on Virus Particles Serological Assays 1327 Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered 1328 COVID-19 Patients N-terminal domain antigenic 1331 mapping reveals a site of vulnerability for SARS-CoV-2 Recurrent deletions in the SARS-CoV-2 spike 1334 glycoprotein drive antibody escape A Study to Evaluate Efficacy, Safety, and Immunogenicity of 1337 mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent Longitudinal Serological 1340 Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent 1341 Patients The 1344 Advisory Committee on Immunization Practices' Interim Recommendation for Moderna COVID-19 Vaccine -United States The Advisory 1349 Committee on Immunization Practices' Interim Recommendation for Use of Janssen 1350 COVID-19 Vaccine -United States SARS-CoV-2 1354 Infections and Serologic Responses from a Sample of UCSF ChimeraX: Structure visualization for 1358 researchers, educators, and developers Pfizer and BioNTech Confirm High Efficacy and No Serious 1360 Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline 1361 Analysis of Landmark COVID-19 Vaccine Study Mapping 1364 Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding 1365 Domain by Structure-Guided High-Resolution Serology Safety and Efficacy of the 1368 BNT162b2 mRNA Covid-19 Vaccine Cross-Sectional 1371 Evaluation of Humoral Responses against SARS-CoV-2 Spike cryoSPARC: 1376 algorithms for rapid unsupervised cryo-EM structure determination Broad and potent 1380 activity against SARS-like viruses by an engineered human monoclonal antibody Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis 1384 of tumor cells Convergent antibody responses 1387 to SARS-CoV-2 in convalescent individuals Alignment of cryo-EM movies of 1389 individual particles by optimization of image translations Conceptual Approaches to Modulating Antibody Effector 1391 Functions and Circulation Half-Life Antibody 1394 potency, effector function, and combinations in protection and therapy for SARS-CoV-2 1395 infection in vivo Prevention of overfitting in cryo-EM structure 1397 determination Analysis of a SARS-CoV-2-1400 Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited 1401 Somatic Mutation Cell entry 1403 mechanisms of SARS-CoV-2 Safety and Efficacy of the BNT162b2 1405 mRNA Covid-19 Vaccine Mouse model 1407 recapitulating human Fcgamma receptor structural and functional diversity The N-terminal domain of spike glycoprotein mediates 1411 SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN Humoral 1415 and cellular immune responses against SARS-CoV-2 variants and human coronaviruses 1416 after single BNT162b2 vaccination Structure-based development of three-and four-antibody 1419 cocktails against SARS-CoV-2 via multiple mechanisms Neutralizing and 1422 protective human monoclonal antibodies recognizing the N-terminal domain of the 1423 SARS-CoV-2 spike protein A single dose of the 1426 SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T 1427 cell responses Human 1430 monoclonal antibody combination against SARS coronavirus: synergy and coverage of 1431 escape mutants Potent binding of 2019 novel coronavirus spike protein by a SARS 1434 coronavirus-specific human monoclonal antibody Defining rules governing recognition and Fc-1437 mediated effector functions to the HIV-1 co-receptor binding site Structural Basis for 1439 Epitopes in the gp120 Cluster A Region that Invokes Potent Effector Cell Activity Ultrapotent human 1443 antibodies protect against SARS-CoV-2 challenge via multiple mechanisms Live Imaging of 1447 SARS-CoV-2 Infection in Mice Reveals Neutralizing Antibodies Require Fc Function for 1448 Optimal Efficacy Live imaging of 1451 SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function 1452 for optimal efficacy Prevalent, protective, and 1455 convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes Safety and efficacy 1459 of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis 1460 of four randomised controlled trials in Brazil, South Africa, and the UK Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein A human 1467 monoclonal antibody blocking SARS-CoV-2 infection CoV-2 require intact Fc effector functions for optimal therapeutic protection Structural 1474 Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Cryo-EM structure of the 2019-nCoV spike in the 1478 prefusion conformation Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, 1482 China A noncompeting pair of human neutralizing antibodies block COVID-19 1485 virus binding to its receptor ACE2 An Infectious cDNA Clone of 1488 SARS-CoV-2 CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-1492 19 A highly conserved cryptic epitope in the receptor binding domains of 1495 SARS-CoV-2 and SARS-CoV New tools for automated high-resolution cryo-EM structure 1498 Compromised Humoral Functional Evolution 1501 Tracks with SARS-CoV-2 Mortality The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC CV3-13 WT CV3-13 LALA CV3-13 GASDALIE CV3-1 MOCK infected cells SARS-CoV-2 inoculated cells (N-) SARS-CoV-2 inoculated cells potent Fc-effector functions -Fc-enhanced CV3-13 delays virus spread and death in SARS-CoV-2-challenged mice -Fc-enhanced CV3-13 synergizes with Fc-compromised nAb to protect 100 % of the mice eTOC Blurb The in vivo impact of non-nAb on SARS-CoV-2 infection is unclear. Here, Beaudoin-Bussières et al. show that Fc-enhanced version of non-nAb CV3-13, delays SARS-CoV-2 spread and death in mice a SYBR Green Real-time PCR assay for determining copies of SARS-CoV-2 N gene 865 RNA using primers SARS-CoV-2 N F: 5'-ATGCTGCAATCGTGCTACAA-3' and 866 SARS-CoV-2 N R: 5'-GACTGCCGCCTCTGCTC-3'. RNA extracted from the 867 corresponding tissues of uninfected mice were used for normalization of N mRNA copy 868 numbers. We observe a Ct value ranging between 38 and 40 in uninfected samples with 869 our primer set and conditions. Therefore we used a Ct value of 38 (lower end) to 870 normalize all the data for estimating N RNA levels. 871Second, serially diluted clarified tissue homogenates were used to infect Vero-E6 cell 872 culture monolayer. We used nanoluciferase activity as a shorter surrogate for plaque 873 assay. Infected cells were washed with PBS and then lysed using 1X Passive lysis buffer. 874The lysates transferred into a 96-well solid white plate (Costar Inc) and nanoluciferase 875 activity was measured using Tristar multiwell Luminometer (Berthold Technology, Bad HEX-IL6, TEX615-CCL2, Cy5-CXCL10, and Cy5.5-IFNgamma. The reaction plate was 889 analyzed using CFX96 touch real time PCR detection system. Scan mode was set to all 890 channels. The PCR conditions were 95 °C 2 min, 40 cycles of 95 °C for 10 s and 60 °C 891 for 45 s, followed by a melting curve analysis to ensure that each primer pair resulted in 892 amplification of a single PCR product. mRNA levels of Il6, Ccl2, Cxcl10 and Ifng in the 893 cDNA samples of infected mice were normalized to gapdh with the formula ΔCt(target 894 gene)=Ct(target gene)-Ct(gapdh). The fold increase was determined using 2 -ΔΔCt method 895 comparing treated mice to uninfected controls. 896 897 FreeStyle 293F cells (Thermo Fisher) were grown in FreeStyle 293F medium (Thermo 899 Fisher) to a density of 1x10 6 cells/mL at 37°C with 8% CO2 with regular agitation (135 900 rpm). Cells were transfected with a plasmid coding for recombinant stabilized SARS-901CoV-2 ectodomain (residue 1-1208) (S-6P or HexaPro Spike; obtained from Dr. Jason S. 902McLellan) (Hsieh et al., 2020) , his-tagged SARS-CoV-2 RBD (residue 319-541) or 903 SARS-CoV RBD-SD1(residue 306-577) using polyethylenimine (PEI). One-week post-904 transfection, supernatants were clarified and filtered using a 0.22 µm filter (Thermo 905Fisher Scientific). The crude S-6P was purified on strep-tactin resin (IBA) followed by 906 size-exclusion chromatography on Superose 6 10/300 column (GE Healthcare) in 10 mM 907Tris pH 8.0 and 200 mM NaCl (SEC buffer). RBD was purified on a Ni-NTA column 908 (Invitrogen) followed by size-exclusion chromatography on a Hiload 16/600 Superdex 909 200pg column using the same SEC buffer. For CryoEM protein sample preparation, the 910 J o u r n a l P r e -p r o o f expression plasmid encoding S-6P was transfected into 293F GnT1-cells using PEI. The 911 protein was harvested and purified with the same protocol as above. The C-terminal twin-912Strep-Tag and 8xHis tag on S-6P was removed by HRV3C (Sigma) digestion as 913 described in (Wrapp et al., 2020b) and the cleaved protein was further purified on a Ni-914 NTA column followed by gel filtration on a Superose 6 10/300 in SEC buffer. Purified 915 proteins were snap-frozen in liquid nitrogen and stored in aliquots at -80°C until further 916 use. Protein purity was confirmed by SDS-PAGE. 917The expression plasmids encoding the heavy and light chains of CV3-13 IgG were 918 transiently transfected into Expi293F cells (Thermo Fisher) using ExpiFectamine 293 919 transfection reagent as per the manufacturer's protocol (Thermo Fisher). After 6-days 920 post-transfection, the antibody was purified on Protein A resin from cell supernatant 921 (Thermo Fisher) before the overnight papain digestion at 37°C using immobilized papain 922 agarose (Thermo Fisher). The resulting Fab was separated from Fc and undigested IgG 923 by passage over protein A resin. Fab was further purified by gel filtration using a 924 Superose 6 10/300 column before use in SPR binding or cryo-EM sample preparation. processing workflow is shown in Figure S4 and statistics of data collection, 1156 reconstruction and refinement is described in Table S1 . The epitope interface analysis 1157 was performed in PISA (Krissinel and Henrick, 2007) .